~~<i id='094C81F069'><strike id='094C81F069'><tt id='094C81F069'><pre id='094C81F069'></pre></tt></strike></i>~~

Home» explore» entertainment

entertainment

author：focus 2025-09-27 20:33:56 Page View：1

CMS Administrator Chiquita Brooks-LaSure Chip Somodevilla/Getty Images

WASHINGTON — Eli Lilly’s latest anti-amyloid Alzheimer’s treatment seems to slow the disease, the company announced this week — news that adds even more pressure on Medicare’s unprecedented restrictions on coverage.

Medicare has so far held firm on its plans to require patient registries for the entire class of anti-amyloid Alzheimer’s drugs, even after they are fully approved.

Pharmaceutical groups and patient advocates are increasingly fighting that approach.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Create a giant ice tray with this foil pan hack to keep food cold this summer
Next article： Activists slam private health insurers over coverage restrictions

leisure time

Medicare details structure of new drug price negotiation program

MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

Moderna hits safety problems in bold bid to reinvent medicine

AramBoghosianforSTATSANFRANCISCO—ModernaTherapeutics,themosthighlyvaluedprivatecompanyinbiotech,hasr

What does generative AI mean for health care? We asked experts

MikeReddyforSTATHealthcarecompaniesareracingtoincorporategenerativeAItoolsintotheirproductpipelinesa

Biden declares emergency in flood

LiveAgeneralviewofafloodedarea,inLudlow,Vt.,July10,2023.Instagram@henrysweatherchannel/viaReutersU.S